TILTomorrow today: dynamic factors predicting changes in intracranial pressure treatment intensity after traumatic brain injury

4

5 Shubhayu Bhattacharyay^{1,2,3,*}, Florian D van Leeuwen⁴, Erta Beqiri⁵, Cecilia

6 Åkerlund⁶, Lindsay Wilson⁷, Ewout W Steyerberg⁴, David W Nelson⁶, Andrew I R

7 Maas^{8,9}, David K Menon¹, Ari Ercole^{1,10}, and the CENTER-TBI investigators and

- 8 participants[†]
- 9
- ¹Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.
- ²Department of Clinical Neurosciences, University of Cambridge, Cambridge, United
 Kingdom.
- ¹³ ³Harvard Medical School, Boston, MA, USA.
- ⁴Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden,
- 15 The Netherlands.
- ⁵Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge,
- 17 Cambridge, United Kingdom.
- ⁶Department of Physiology and Pharmacology, Section for Perioperative Medicine and
- 19 Intensive Care, Karolinska Institutet, Stockholm, Sweden.
- ²⁰ ⁷Division of Psychology, University of Stirling, Stirling, United Kingdom.
- ²¹⁸Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
- ⁹Department of Translational Neuroscience, Faculty of Medicine and Health Science,
- 23 University of Antwerp, Antwerp, Belgium.
- ¹⁰Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.
- 26 *Corresponding author: <u>sb2406@cam.ac.uk</u> (SB)
- ¹A full list of the CENTER-TBI investigators and participants are listed after the
- 28 acknowledgements.

29 **ABSTRACT**

30

Practices for controlling intracranial pressure (ICP) in traumatic brain injury (TBI) patients 31 admitted to the intensive care unit (ICU) vary considerably between centres. To help 32 understand the rational basis for such variance in care, this study aims to identify the 33 34 patient-level predictors of changes in ICP management. We extracted all heterogeneous data (2,008 pre-ICU and ICU variables) collected from a prospective cohort (n=844, 51 35 ICUs) of ICP-monitored TBI patients in the Collaborative European NeuroTrauma 36 37 Effectiveness Research in TBI (CENTER-TBI) study. We developed the TILTomorrow modelling strategy, which leverages recurrent neural networks to map a token-embedded 38 time series representation of all variables (including missing values) to an ordinal, 39 dynamic prediction of the following day's five-category therapy intensity level (TIL^(Basic)) 40 score. With 20 repeats of 5-fold cross-validation, we trained TILTomorrow on different 41 variable sets and applied the TimeSHAP (temporal extension of SHapley Additive 42 43 exPlanations) algorithm to estimate variable contributions towards predictions of next-day changes in TIL^(Basic). Based on Somers' D_{xy} , the full range of variables explained 68% 44 (95% CI: 65–72%) of the ordinal variation in next-day changes in TIL^(Basic) on day one and 45 up to 51% (95% CI: 45–56%) thereafter, when changes in TIL^(Basic) became less frequent. 46 Up to 81% (95% CI: 78–85%) of this explanation could be derived from non-treatment 47 variables (i.e., markers of pathophysiology and injury severity), but the prior trajectory of 48 ICU management significantly improved prediction of future de-escalations in ICP-49 50 targeted treatment. Whilst there was no significant difference in the predictive discriminability (i.e., area under receiver operating characteristic curve [AUC]) between 51 next-day escalations (0.80 [95% CI: 0.77–0.84]) and de-escalations (0.79 [95% CI: 0.76– 52 0.82]) in TIL^(Basic) after day two, we found specific predictor effects to be more robust with 53 de-escalations. The most important predictors of day-to-day changes in ICP management 54 included preceding treatments, age, space-occupying lesions, ICP, metabolic 55 56 derangements, and neurological function. Serial protein biomarkers were also important and may serve a useful role in the clinical armamentarium for assessing therapeutic 57 needs. Approximately half of the ordinal variation in day-to-day changes in TIL^(Basic) after 58 59 day two remained unexplained, underscoring the significant contribution of unmeasured factors or clinicians' personal preferences in ICP treatment. At the same time, specific 60 dynamic markers of pathophysiology associated strongly with changes in treatment 61 62 intensity and, upon mechanistic investigation, may improve the timing and personalised targeting of future care. 63

64 MAIN TEXT

65

66 Introduction

67

When traumatic brain injury (TBI) patients are admitted to the intensive care unit (ICU), a 68 core focus of their care is to protect and promote potential recovery in brain tissue by 69 either preventing or mitigating raised intracranial pressure (ICP).¹ To date, the 70 heterogeneous pathophysiological mechanisms that elevate ICP after TBI are not 71 sufficiently characterised for patient-tailored treatment (i.e., precision medicine).^{2,3} 72 Therefore, consensus-based guidelines^{4,5} encourage a precautionary, stepwise 73 approach⁶ to ICP management, in which therapeutic intensity – defined by the perceived 74 risk and complexity of each treatment plan - is incrementally escalated until adequate 75 ICP control is achieved. The overall intensity of a patient's ICP management can be 76 measured on the latest Therapy Intensity Level (TIL) scale,⁷ which was developed by the 77 interagency TBI Common Data Elements (CDE) scheme⁸ and prospectively validated 78 thereafter.^{7,9} 79

80

An analysis of high-TIL treatment administration across 52 ICUs participating in the 81 82 Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study^{10,11} revealed frequent deviation from the recommended stepwise approach, even 83 with ICP monitoring.¹² In fact, there was substantial between-centre variation in ICP 84 management (according to TIL) without commensurate variation in six-month functional 85 outcome on the Glasgow Outcome Scale – Extended (GOSE).^{13,14} Baseline injury 86 severity factors, imaging results, and ICP explained only 8.9% of the pseudo-variance in 87 dichotomised high-TIL treatment use.¹² These results raised the guestions about whether 88 contemporary ICP management is performed in a systematic, rational manner in practice 89 and whether some patients are being exposed to unnecessary risks with high-TIL 90 therapies. Answering these questions requires consideration of a patient's full, time-91 varying clinical course as well as a more detailed representation of different levels of the 92 TIL scale. 93

94

95 As a first step towards answering the questions above, we aim to identify factors associated with ICP-targeted treatment decisions on an individual patient level. 96 Expanding upon our previous work,^{13,15} we propose a modelling strategy (TILTomorrow) 97 which dynamically predicts next-day TIL^(Basic) – the five-category version of TIL – from all 98 pre-ICU and ICU data prospectively recorded for the CENTER-TBI study (Fig. 1). Our 99 primary objective in developing TILTomorrow was to determine how well a patient's full 100 101 clinical course can predict upcoming changes in ICP treatment intensity. Our second objective was to estimate the differential contribution of pathophysiological severity, the 102 preceding trajectory of treatment, and unmeasured factors (e.g., personal treatment 103 preferences) towards explanation of next-day changes made to TIL^(Basic). Our third 104 105 objective was to mine the full dataset for dynamic predictors of day-to-day changes in TIL (Basic) 106



110 are 95% confidence intervals derived using bias-corrected bootstrapping (1,000 resamples) to represent 111 the variation across the patient population and across the 20 repeated five-fold cross-validation partitions. 112 (a) Illustration of the TILTomorrow dynamic prediction task on a sample patient's timeline of ICU stay. The 113 objective of the task is to predict the next-day TIL^(Basic) score at each calendar day of a patient's ICU stay. 114 The prediction is dynamic, updated for each calendar day, and must account for temporal variation of 115 variables across all preceding days using a time-series model (f_t). (b) Illustration of the TILTomorrow 116 modelling strategy on a sample patient's timeline of ICU stay. Each patient's ICU stay is first discretised

117 into non-overlapping time windows, one for each calendar day. From each time window, values for up to 118 979 dynamic variables were combined with values for up to 1.029 static variables to form the variable set. 119 The variable values were converted to tokens by discretising numerical values into 20-guantile bins from 120 the training set and removing special formatting from text-based entries. Through an embedding layer, a 121 vector was learned for each token encountered in the training set, and tokens were replaced with these 122 vectors. A positive relevance weight, also learned for each token, was used to weight-average the vectors 123 of each calendar day into a single, low-dimensional vector. The sequence of low-dimensional vectors 124 representing a patient's ICU stay were fed into a gated recurrent neural network (RNN). The RNN outputs 125 were then decoded at each time window into an ordinal prognosis of next-day TIL^(Basic) score. The highestintensity treatments associated with each threshold of TIL^(Basic) are decoded in Table 1. (c) Probability 126 calibration slope, at each threshold of next-day TIL^(Basic), for models trained on the full variable set. The 127 ideal calibration slope of one is marked with a horizontal orange line. (d) Ordinal probability calibration 128 129 curves at four different days after ICU admission. The diagonal dashed line represents the line of perfect 130 calibration. The values in each panel correspond to the maximum absolute error (95% confidence interval) 131 between the curve and the perfect calibration line. Abbreviations: CT=computerised tomography, 132 ER=emergency room, f_t =time-series model, GRU=gated recurrent unit, Hx=history, ICP=intracranial 133 pressure, ICU=intensive care unit, LSTM=long short-term memory, N/A=not available, NF-L=neurofilament light chain, SES=socioeconomic status, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category 134 135 TIL scale as defined in Table 1, VE=vascular endothelial.

136

137 Methods

138

139 Study design and participants

140

CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65 141 medical centres across 18 European countries and Israel.^{10,11} Patients were recruited 142 between 19 December 2014 and 17 December 2017 if they met the following criteria: (1) 143 presentation within 24 hours of a TBI, (2) clinical indication for a computerised 144 tomography (CT) scan, and (3) no severe pre-existing neurological disorder. In 145 accordance with relevant laws of the European Union and the local country, ethical 146 approval was obtained for each site, and written informed consent by the patient or legal 147 representative was documented electronically. The list of sites, ethical committees, 148 approval numbers, and approval dates can be found online: https://www.center-149 tbi.eu/project/ethical-approval. The project objectives and design of CENTER-TBI have 150 been described in detail previously.^{10,11} 151

152

In this work, we apply the following additional inclusion criteria: (1) primary admission to the ICU, (2) at least 16 years old at ICU admission, (3) at least 24 hours of ICU stay, (4) invasive ICP monitoring, (5) no decision to withdraw life-sustaining therapies (WLST) on the first day of ICU stay, and (6) availability of daily TIL assessments from at least two consecutive days.

158

159 Therapy intensity level (TIL)

160

161 The endpoint for the TILTomorrow dynamic prediction task (Fig. 1a) is the next-day 162 TIL^(Basic) score. The TIL^(Basic) scale was developed through an international expert panel 163 to serve as a five-category summary of the full, 38-point TIL score.⁸ TIL^(Basic) categorises 164 overall ICP treatment intensity over a given period of time by selecting the highest

classification of ICP control amongst all treatments administered in that period of time, as 165 defined in Table 1. By convention, a decompressive craniectomy for refractory intracranial 166 hypertension is scored with TIL^(Basic)=4 (i.e., extreme ICP control) for every subsequent 167 168 timepoint. As described later, we account for this effect in our analysis by: (1) referencing TILTomorrow performance against simply carrying forward the last-available TIL^(Basic) 169 score and against models trained without treatment (e.g. incidence of decompressive 170 craniectomy) or clinician-impression (e.g., reason for decompressive craniectomy) 171 variables, and (2) focusing only on variables that occur at least a day before a change in 172 TIL^(Basic). Since daily use of TIL^(Basic) was prospectively validated,⁷ we calculate the 173 TIL^(Basic) score over each available calendar day of a patient's ICU stay. For the CENTER-174 TBI study, information pertaining to the TIL^(Basic) treatments (Table 1) was recorded on 175 days 1–7, 10, 14, 21, and 28 of ICU stay. TIL^(Basic) score calculations were excluded on 176 or after the day of any WLST decision. As an overall summary metric, we also calculated 177 TIL^(Basic)_{median} – the median of the daily TIL^(Basic) scores over days 1–7 of ICU stay. 178

179

We elected not to use the full TIL score as the model endpoint since it is a point-sum (rather than a truly categorical) score, and the same value changes in TIL can be the result of changing treatments across different intensities. For instance, administering head elevation, low-volume cerebrospinal fluid drainage, and low-dose mannitol is numerically 'equivalent' to performing a last-resort decompressive craniectomy.⁷ On the contrary, changes in TIL^(Basic) correspond to transitions across specific, interpretable bands of treatment intensity (Table 1).

Classification of ICP control	ICP-targeting treatment	Study representation (count)		
		Patients (844 total)	Centres (51 total)	
(4) Extreme		490 (58%)	50 (98%)	
	High-dose propofol or barbiturates (metabolic suppression)	315 (37%)	46 (90%)	
	Intensive hyperventilation (P _a CO ₂ <30 mmHg)	61 (7.2%)	24 (47%)	
	Therapeutic hypothermia (<35°C)	93 (11%)	31 (61%)	
	Intracranial operation for progressive mass lesion (not scheduled at admission)	149 (18%)	40 (78%)	
	Decompressive craniectomy for refractory intracranial hypertension*	76 (9.0%)	29 (57%)	
(3) Moderate		344 (41%)	47 (92%)	
	High-volume CSF drainage (≥120 mL/24h)	212 (25%)	41 (80%)	
	Moderate hyperventilation (30≤P _a CO ₂ <35 mmHg)	235 (28%)	41 (80%)	
	Higher-dose mannitol (>2g/kg/24h)	45 (5.3%)	22 (43%)	
	Higher-dose hypertonic saline (>0.3g/kg/24h)	128 (15%)	33 (65%)	
	Cooling for ICP control (≥35°C)	146 (17%)	32 (63%)	
(2) Mild		645 (76%)	50 (98%)	
	Higher-dose sedation for ICP control (not aiming for burst suppression)	561 (66%)	48 (94%)	
	Low-volume CSF drainage (<120 mL/24h)	221 (26%)	41 (80%)	
	Fluid loading for CPP management	511 (61%)	48 (94%)	
	Vasopressor therapy for CPP management	720 (85%)	50 (98%)	
	Mild hyperventilation $(35 \le P_a CO_2 \le 40 \text{ mmHg})$	509 (60%)	48 (94%)	
	Lower-dose mannitol (≤2g/kg/24h)	197 (23%)	41 (80%)	
	Lower-dose hypertonic saline (≤0.3g/kg/24h)	303 (36%)	41 (80%)	
(1) Basic		406 (48%)	45 (88%)	
	Head elevation for ICP control	765 (91%)	50 (98%)	
	Nursed flat (180°) for CPP management	123 (15%)	31 (61%)	
	Lower-dose sedation for mechanical ventilation	753 (89%)	50 (98%)	
(0) None		338 (40%)	48 (94%)	

188 Table 1. TIL^(Basic) scale treatments and representation in study population

189 The TIL^(Basic) scale was developed by Maas *et al.*⁸ and prospectively validated by Bhattacharyay *et al.*⁷ The TIL^(Basic) score is determined by selecting

190 the highest classification of ICP control (first column) among all the ICP-targeting treatments (second column) administered to a patient over a

191 calendar day. The study representation of each TIL^(Basic) category and each ICP-targeting treatment is the count (and percentage) of patients who

received the corresponding (category of) treatment in the study population as well as the count (and percentage) of centres who administered the

193 corresponding (category of) treatment in the study population.

194 *If a decompressive craniectomy is performed as a last resort for refractory intracranial hypertension, its score is included in the day of the operation 195 and in every subsequent day of ICU stay.

Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, ICU=intensive care unit, P_aCO₂=partial pressure of carbon dioxide in arterial blood. TIL=Therapy Intensity Level scale. TIL^(Basic)=condensed TIL scale.

198 *Model variables*

199

We extracted all variables collected before and during ICU stays for the CENTER-TBI 200 core study¹¹ (v3.0, ICU stratum) using Opal database software.¹⁶ These variables were 201 sourced from medical records and online test results and include structured (i.e., 202 numerical, binary, or categorical), unstructured (i.e., free text), and missing values. We 203 manually excluded variables which explicitly indicate death or WLST (Supplementary 204 Table S1), and, if a decision to WLST was made during any point of a patient's ICU stay, 205 we only extracted model variables before the timestamp of WLST decision. We also 206 207 added features extracted from automatically segmented and expert-corrected highresolution CT and magnetic resonance (MR) images. These features correspond to the 208 type, location, and volume of space-occupying lesions, and the process of their extraction 209 has been described in detail previously.^{17,18} In total, we included 2,008 variables: 1,029 210 static (i.e., fixed at ICU admission) variables and 979 dynamic variables (i.e., collected 211 during ICU stay) with varying sampling frequencies. We qualitatively organised the 212 variables into the nine categories listed in Table 2 and further indicated whether variables 213 represented an intervention during ICU admission (e.g., administration and type of 214 glucose management) or a physician-based impression (e.g., reason for not pursuing 215 intracranial surgery following CT scan, Supplementary Table S2). Descriptions for each 216 of the variables can be viewed online at the CENTER-TBI data dictionary: 217 218 https://www.center-tbi.eu/data/dictionary.

219 220

Table 2. Variable count per category and subtype

Category	Example variable	Count by subtypes				
		All	Static	Dynamic	Interventions and physician impressions	
Demographics and socioeconomic status	Years of formal education	22	22	0	0	
Medical and behavioural history	Number of prior TBIs or concussions	186	186	0	0	
Injury characteristics and severity	Airbag deployed during accident	84	84	0	0	
Emergency care and ICU admission	Blood transfusion in ER	234	234	0	14	
Brain imaging reports	Cortical sulcal effacement	939	425	514	19	
Laboratory measurements	Serum level of UCH-L1	228	75	153	6	
ICU medications and management	Vasopressor dose	141	3	138	127	
ICU vitals and assessments	Types of seizures in past day	125	0	125	0	
Surgery and neuromonitoring	Ventriculostomy for CSF drainage	49	0	49	39	
Total		2008	1029	979	205	

221 Data represent the number of subtype (*column*) variables per category (*row*).

Abbreviations: CSF=cerebrospinal fluid, ER=emergency room, ICU=intensive care unit, SBP=systolic blood

223 pressure, TBI=traumatic brain injury, UCH-L1=ubiquitin carboxy-terminal hydrolase L1.

224

225 **TILTomorrow modelling strategy**

Whilst strong predictors of functional outcome after TBI are known, this is not the case 227 for TIL. Thus, the TILTomorrow modelling strategy was designed to include all static and 228 dynamic variables from CENTER-TBI to produce an evolving prediction of the next 229 230 calendar day's TIL^(Basic) over each patient's ICU stay. The large number of variables precludes building such a model by manual feature extraction, motivating our flexible 231 tokenisation-and-embedding approach with no constraints on the number or type of 232 variables per patient. We trained models, through supervised machine learning, with three 233 main components based on our prior studies^{13,15,19}: (1) a token-embedding encoder, (2) 234 a gated recurrent neural network (RNN), and (3) an ordinal endpoint output layer. We 235 created 100 partitions of our patient population for repeated k-fold cross-validation (20 236 237 repeats, 5 folds) with 15% of each training set randomly set aside as an internal validation 238 set.

239

ICU stays were partitioned into non-overlapping time windows, one per calendar day (Fig. 240 1a). Static variables were carried forward across all windows (Fig. 1b). All variables were 241 tokenised through one of the following methods: (1) for categorical variables, appending 242 243 the value to the variable name, (2) for numerical variables, learning the training set distribution and discretising into 20 quantile bins, (3) for text-based entries, removing all 244 special characters, spaces, and capitalisation from the text and appending to the variable 245 246 name, and (4) for missing values, creating a separate token to designate missingness (Fig. 1b). We selected 20 quantile bins for discretisation based on optimal performance 247 in our previous work.^{13,19} By labelling missing values with separate tokens instead of 248 imputing them, the models could learn potentially significant patterns of missingness and 249 integrate a diverse range of missing data without needing to validate the assumptions of 250 imputation methods on each variable.²⁰ During training, the models learned a low-251 dimensional vector (of either 128, 256, 512, or 1,024 units) and a 'relevance' weight for 252 each token in the training set. Therefore, models would take the unique tokens from each 253 time window of a patient, replace them with the corresponding vectors, and average the 254 vectors – each weighted by its corresponding relevance score – into a single vector per 255 time window (Fig. 1b). 256

257

Each patient's sequence of low-dimensional vectors then fed into a gated RNN – either a 258 259 long short-term memory (LSTM) network or a gated recurrent unit (GRU) – to output another vector per time window. In this manner, the models learned temporal patterns of 260 variable interactions from training set ICU records and updated outputs with each new 261 time window of data. Finally, each RNN output vector was decoded with a multinomial 262 (i.e., softmax) output layer to return a probability at each threshold of next-day TIL^(Basic) 263 over time (Fig. 1b). From these outputs, we also calculated the probabilities of TIL^(Basic) 264 265 decreasing, staying the same, or increasing tomorrow in relation to the last available TIL^(Basic) score (Supplementary Methods S1). Please note that both threshold-level 266 probability estimates and estimated probabilities of next-day changes in TIL^(Basic) are 267 268 derived from the outputs of the same model, as described in Supplementary Methods S1. 269

The combinations of hyperparameters – in addition to those already mentioned (embedding vector dimension and RNN type) – and the process of their optimisation in the internal validation sets are reported in Supplementary Methods S2–S3.

273

274 Model and information evaluation

275

All metrics, curves, and associated confidence intervals (CIs) were calculated on the testing sets using the repeated Bootstrap Bias Corrected Cross-Validation (BBC-CV) method,²¹ as described in Supplementary Methods S2. We calculated metrics and CIs at each day directly preceding a day of TIL assessment in our study population (i.e., days 1–6, 9, 13, 20, and 27).

281

The reliability of model-generated prediction trajectories was assessed through the calibration of output probabilities at each threshold of next-day TIL^(Basic). Using the logistic recalibration framework,²² we first measured calibration slope. Calibration slope less(/greater) than one indicates overfitting(/underfitting).²² Additionally, we examined smoothed probability calibration curves to detect miscalibrations that might have been overlooked by the logistic recalibration framework.²²

- 288 To evaluate prediction discrimination performance, we calculated the area under the 289 receiver operating characteristic curve (AUC) at each threshold of next-day TIL^(Basic). 290 These AUCs are interpreted as the probability of the model correctly discriminating a 291 patient whose next-day TIL^(Basic) is above a given threshold from one with next-day 292 TIL^(Basic) below. Moreover, we calculated the AUC for prediction of next-day escalation 293 and de-escalation in TIL^(Basic). In this case, the AUC represents the probability of the 294 model correctly discriminating a patient who experienced a day-to-day (de-)escalation in 295 TIL^(Basic) from one who did not. 296
- 297

We also assessed the information quality achieved by the combination of our modelling strategy and the CENTER-TBI variables in predicting next-day changes in $TIL^{(Basic)}$ by calculating Somers' D_{xy} .²³ In our context, Somers' D_{xy} is interpreted as the proportion of ordinal variation in day-to-day changes of $TIL^{(Basic)}$ that is explained by the variation in model output.²⁴ The calculation of Somers' D_{xy} is detailed in Supplementary Methods S4.

We compared the performance of the TILTomorrow modelling strategy trained on the 304 following factors to test their differential contribution to prediction: (1) the full variable set 305 [2,008 variables], (2) all variables excluding physician-based impressions and treatments 306 307 (e.g., all variables related to TIL) [1,803 variables], and (3) only static variables repeated in each time window [1,029 variables]. Our rationale for these ablated variable sets was 308 309 to estimate the extent to which: (1) predictable trajectories of care – independent of other measured factors - influence treatment planning and (2) ICP treatments are responding 310 to recorded events that occur over a patient's ICU stay. To serve as our reference for 311 model comparison, we also calculated the performance achieved by simply carrying over 312 313 the last available TIL^(Basic) for prediction of next-day TIL^(Basic). This reference performance accounts not only for the proportion of the population that did not change in TIL^(Basic) on a 314 given day but also for the change in the assessment population caused by patient 315 discharge over time. 316

318 **Contributors to transitions in TIL**

319

We applied the TimeSHAP algorithm²⁵ on testing set predictions to find specific variables 320 associated with next-day changes in TIL^(Basic). TimeSHAP is a temporal extension of the 321 kernel-weighted SHapley Additive exPlanations (KernelSHAP) algorithm,²⁶ which 322 estimates the relative contribution (i.e., Shapley value²⁷) of each model input to a specific 323 patient's model output. In our case, this was done by masking sampled combinations of 324 325 tokens (i.e., coalitions) leading up to a patient's next-day change in TIL^(Basic) and calculating the difference in trained model output for each combination. A kernel-weighted 326 linear regression model was then fit between binary coalition masks and resulting model 327 outputs to estimate the Shapley value for each model input. TimeSHAP extends 328 329 KernelSHAP by considering each unique combination of tokens and time windows as its own feature. Crucially, TimeSHAP made this computationally tractable for our application, 330 331 in which models contain many possible tokens, by grouping low-contributing time windows in the distant past together as a single feature (i.e., temporal coalition pruning). 332 TimeSHAP, KernelSHAP, and Shapley values are described in greater, mathematical 333 detail in Supplementary Methods S5. 334

335

We estimated token-level Shapley values with the TimeSHAP algorithm at both one day 336 and two days before an upcoming change in TIL^(Basic). Our chosen model output for 337 TimeSHAP was the expected next-day TIL(Basic) score, as defined in Supplementary 338 Methods S5. We then calculated the difference between the estimated Shapley values of 339 the two consecutive days for each token to derive its Δ TimeSHAP value. If a token did 340 341 not exist in the window of either of the two days, then its Shapley value for that day was zero. Therefore, ΔTimeSHAP values were interpreted as the contributions of variable 342 tokens towards the difference in model prediction of next-day TIL^(Basic) over the two days 343 directly preceding the change in TIL^(Basic), given the patient's full set of tokens. If a variable 344 had a positive (or negative) Δ TimeSHAP value, it was associated with an increased 345 likelihood of escalation (or de-escalation) in next-day treatment intensity. Moreover, since 346 347 the calculation of Δ TimeSHAP values required two days of information before the change in TIL^(Basic), we only calculated the variable contributions to day-to-day changes in TIL^(Basic) 348 that occurred after day two of ICU stay. 349

350

351 **Results**

352

353 Study population

354

Of the 4,509 patients available for analysis in the CENTER-TBI core study, 844 patients 355 from 51 ICUs met the inclusion criteria of this work (Supplementary Fig. S1). The median 356 ICU stay duration of our population was 14 days (Q_1-Q_3 : 8.4–23 days) and 86% (*n*=722) 357 stayed through at least seven calendar days. Since the regularity of TIL^(Basic) assessments 358 decreased substantially after 14 days, and since less than half of the population remained 359 in the ICU for 21 days (Supplementary Fig. S2), we focused our analysis on the first 14 360 days of ICU stay. Summary characteristics of the overall population as well as those 361 stratified by whether patients had a day-to-day change in TIL^(Basic) over their first week in 362

the ICU are detailed in Table 3. On average, patients who did not experience a change in TIL^(Basic) over their first week were significantly younger, had higher baseline ICP values, and resulted in poorer functional recovery at six months post-injury (Table 3). However, their mean ICU stay duration was not significantly different.

367

368	Table 3.	Summary	characteristics	of th	e study	population	stratified	by	day-to-day	changes	in
369	TIL ^(Basic)	_			_			-		-	

Summary characteristic	Overall	Day-to-day change in TIL ^(Basic) during first week in ICU				
	(<i>n</i> =844, 51 centres)	Yes (<i>n</i> =677, 50 centres)	No (<i>n</i> =167, 40 centres)	<i>p</i> -value [‡]		
Age [years]	47 (29–61)	48 (30–62)	41 (27–58)	0.047		
Sex: Female	212 (25%)	165 (24%)	47 (28%)	0.36		
Baseline Glasgow Coma Scale (n*=795)				0.67		
3–8	540 (68%)	426 (67%)	114 (71%)			
9–12	138 (17%)	112 (18%)	26 (16%)			
13–15	117 (15%)	96 (15%)	21 (13%)			
Baseline CT lesions (<i>n</i> *=730)						
Epidural haematoma	165 (23%)	136 (23%)	29 (19%)	0.36		
Intracerebral haemorrhage	594 (81%)	480 (83%)	114 (77%)	0.11		
Subdural haematoma	465 (64%)	368 (63%)	97 (65%)	0.76		
Traumatic subarachnoid haemorrhage	633 (87%)	502 (86%)	131 (88%)	0.73		
First-day mean ICP [mmHg] (n*=811)	11 (7.0–15)	10. (6.8–14)	12 (8.2–17)	<0.001		
TIL ^(Basic) median	2 (2–4)	2 (2–3)	4 (2–4)	<0.001		
Refractory intracranial hypertension (<i>n</i> *=836)	143 (17%)	85 (13%)	58 (35%)	<0.001		
ICU stay duration [days]	14 (8.4–23)	14 (8.1–23)	14 (8.8–23)	0.90		
Six-month GOSE (<i>n</i> *=738)				0.018		
(1) Death	181 (25%)	139 (23%)	42 (29%)			
(2 or 3) Vegetative/lower SD	181 (25%)	154 (26%)	27 (18%)			
(4) Upper SD	70 (9.5%)	48 (8.1%)	22 (15%)			
(5) Lower MD	122 (17%)	96 (16%)	26 (18%)			
(6) Upper MD	73 (10%)	65 (11%)	8 (5.5%)			
(7) Lower GR	55 (7.5%)	42 (7.1%)	13 (8.9%)			
(8) Upper GR	56 (7.6%)	48 (8.1%)	8 (5.5%)			
Baseline prognosis [†] [%] (<i>n</i> *=749)						
Pr(GOSE>1)	85 (64–94)	85 (66–95)	83 (56–93)	0.010		
Pr(GOSE>3)	54 (31–75)	54 (33–76)	52 (24–71)	0.019		
Pr(GOSE>4)	40. (22–59)	41 (24–60.)	38 (16–54)	0.010		
Pr(GOSE>5)	22 (11–36)	22 (12–38)	19 (8.9–30.)	0.0022		
Pr(GOSE>6)	13 (6.7–21)	13 (7.1–22)	11 (5.2–17)	0.0034		
Pr(GOSE>7)	5.2 (2.5–9.5)	5.4 (2.7–9.9)	4.2 (2.2–8.6)	0.0071		

370 Data are median (Q_1-Q_3) for numerical characteristics and n (% of column group) for categorical

characteristics unless otherwise indicated. Units or numerical definitions of characteristics are provided in
 square brackets.

373 *Limited sample size of non-missing values for characteristic.

[†]Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical
 information in the first 24 hours of ICU stay, as described previously.¹⁵

[‡]*p*-values, comparing patients who experienced a day-to-day change in TIL^(Basic) in the first week of ICU

377 stay to those who did not, are derived from Welch's *t*-test for numeric variables and χ^2 contingency table

378 test for categorical variables.

379 Abbreviations: CT=Computerised tomography, GOSE=Glasgow Outcome Scale-Extended, GR=good 380 recoverv. ICP=intracranial pressure. ICU=intensive care unit. MD=moderate disability. 381 Pr(GOSE>•)="probability of GOSE greater than • at six months post-injury" as previously calculated from the first 24 hours of admission,²⁷ SD=severe disability, TIL=Therapy Intensity Level scale, 382 TIL^(Basic)=condensed TIL scale as measured in Table 1 for each calendar day, TIL^(Basic)_{median}=median TIL^(Basic) 383 over first week of ICU stay. 384

385

The representation of each ICP-targeting treatment and TIL^(Basic) score in our study is listed in Table 1. The least-represented treatment (higher-dose mannitol) was administered to 45 patients (5.3%) across 22 ICUs, whereas the least-represented TIL^(Basic) score (TIL^(Basic)=1) applied to 344 patients (41%) across 47 ICUs. A decompressive craniectomy for refractory intracranial hypertension was performed in 76 patients (9.0%) across 29 ICUs, and the median timepoint for such an operation was day three (Q_1 – Q_3 : two–five) of ICU stay.

393

The distribution of TIL^(Basic) values at each day of TIL assessment and the transitions of 394 TIL^(Basic) scores between days of assessment are visualised in Fig. 2a. No more than 2.4% 395 of the population's TIL^(Basic) scores were missing at any given assessment day, and the 396 proportion of patients receiving basic-to-no ICP-targeting treatment (i.e., TIL^(Basic)≤1) 397 increased over time (Supplementary Fig. S2). The distribution of day-to-day changes in 398 TIL^(Basic) (Fig. 2b) demonstrates that there was considerably more change in TIL^(Basic) from 399 day one to day two than there was in any other pair of consecutive days. On the rest of 400 the days in the first week, 69–75% of the population did not experience a change in 401 TIL^(Basic) from one day to the next (Fig. 2b). The distribution of next-day TIL^(Basic) given the 402 current day's TIL^(Basic) (Supplementary Fig. S3) show that at least 79% of day-to-day 403 therapeutic transitions happen within one TIL^(Basic) category, except for escalations from 404 TIL^(Basic)=0 and de-escalations from TIL^(Basic)=4 from day one to two. When a change in 405 TIL^(Basic) did occur, the distributions of TIL^(Basic) before and after the change 406 (Supplementary Fig. S4) reflect a gradual trend towards de-escalation at later days of ICU 407 stay as expected. 408



WLST or Died Discharged

411 Fig. 2. Distributions of TIL^(Basic) and its day-to-day changes in the study population. (a) Alluvial diagram of the evolution of the TIL^(Basic) distribution in the study population over the assessed days of ICU 412 stav. Percentages which round to 2% or lower are not shown. (b) Distributions of day-to-day changes in 413 414 TIL^(Basic). The numbers above each bar represent the number of study patients remaining in the ICU after the corresponding day-to-day step. Percentages which round to 2% or lower are not shown. Abbreviations: 415 ICU=intensive care unit, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as 416 defined in Table 1, WLST=withdrawal of life-sustaining therapies. 417

418

Reliability and performance of TILTomorrow 419

420

With both calibration slopes (Fig. 1c) and smoothed calibration curves (Fig. 1d) across 421 the thresholds of next-day TIL^(Basic), we observed that the TILTomorrow modelling strategy 422 achieved sufficient testing set calibration for analysis from day two of ICU stay onwards. 423 The 95% CI of the calibration slope pertaining to prediction of next-day TIL^(Basic) > 0 was 424 wider than that of other thresholds but still centred around a well-calibrated slope of one. 425 426

In the first week of ICU stay, TILTomorrow correctly discriminated patients at each 427 threshold of next-day TIL^(Basic) between 79% (95% CI: 77-82%) and 95% (95% CI: 93-428 429 96%) of the time (Fig. 3a). However, this apparently strong predictive power was in fact largely because TIL^(Basic) tended not to change greatly (i.e., the "inertia" of TIL) across 430 day-to-day steps (Fig. 2b), especially at higher thresholds of next-day TIL^(Basic) (violet lines 431 in Fig. 3a). After removing all treatments and physician-based impressions from the model 432 variable set (including all variables related to TIL), the first-week AUCs dropped to 433 between 0.65 (95% CI: 0.62–0.68) and 0.86 (95% CI: 0.82–0.89) with significantly lower 434 performance at higher thresholds of next-day TIL^(Basic) (Fig. 3a). Models trained with only 435 static variables achieved only marginally better discrimination than an uninformative 436 predictor (best AUC: 0.60 [95% CI: 0.56-0.63], Fig. 3a). 437

medRxiv preprint doi: https://doi.org/10.1101/2024.05.14.24307364; this version posted May 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



Model variable set 💿 Full 💿 Only last available TIL (Basic) 🛛 📀 No treatments 🛛 🔶 No dynamic

Fig. 3. Differential performance in discriminating and explaining next-day TIL^(Basic). All shaded regions 440 441 surrounding curves and error bars are 95% confidence intervals derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across 20 repeated five-fold cross-validation partitions. (a) 442 Discrimination performance in prediction of next-day TIL^(Basic) – measured by AUC at each threshold of 443 TIL^(Basic) – by models trained on different variable sets. The violet line represents the performance achieved 444 445 by simply carrying the last available TIL^(Basic) forward to account for the effect of day-to-day stasis in TIL^(Basic) on prediction. The horizontal dashed line (AUC=0.5) represents the performance of uninformative 446 447 prediction. (b) Discrimination performance in prediction of next-day de-escalation or escalation in TIL^(Basic) 448 - measured by AUC - by models trained on different variable sets. The horizontal dashed line (AUC=0.5) 449 represents the performance of uninformative prediction. (c) Explanation of ordinal variation in next-day 450 changes in TIL^(Basic) – measured by Somers' D_{xy} – by models trained on different variable sets. Abbreviations: AUC=area under the receiver operating characteristic (ROC) curve, ICU=intensive care unit, 451 TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1. 452

453

To completely account for the inertia of TIL^(Basic) across day-to-day steps, we calculated 454 discrimination performance in the prediction of changes in next-day TIL^(Basic) (Fig. 3b). 455 Prediction performance was highest on day one across all variable sets, with the full-456 variable model correctly discriminating next-day de-escalations 90% (95% CI: 88–91%) 457 of the time and next-day escalations 85% (95% CI: 83-87%) of the time. Within each 458 variable set, change-in-TIL^(Basic) prediction performance did not change significantly from 459 day two onwards, except for the prediction of next-day escalation from static variables. 460 Treatment and physician-based impression variables significantly improved performance 461 in prediction of next-day de-escalations in TIL^(Basic) but not in prediction of next-day 462 escalations in TIL^(Basic) (Fig. 3b). Moreover, static variables achieved greater 463

discrimination in the prediction of TIL^(Basic) escalations than in the prediction of TIL^(Basic)
 de-escalations from days two to four of ICU stay.

- 466
- 467

7 Differential explanation of next-day changes in TIL

468

The full set of 2.008 variables explained 68% (95% CI: 65–72%) of the ordinal variation 469 in next-dav changes in TIL^(Basic) on day one and up to 51% (95% CI: 45–56%) through the 470 rest of the first week (Fig. 3c). For the same endpoint, the 1,803 variables which exclude 471 treatments and physician-based impressions explained 60% (95% CI: 57–64%) of the 472 ordinal variation on day one and up to 35% (95% CI: 30–41%) thereafter (Fig. 3c). From 473 Fig. 3b, we found that the explanation added from the prior trajectory of ICU management 474 related more to informative patterns of treatment de-escalation than to those of 475 escalation. At the same time, most of the explanation achieved by the full variable model 476 could also be achieved without explicit information about the patient's treatments. The 477 1,029 static variables explained 54% (95% CI: 50-57%) of the ordinal variation in next-478 day changes in TIL^(Basic) on day one and decreased in explanation significantly from days 479 two (28% [95% CI: 23–33%]) to six (13% [95% CI: 7–19%]) (Fig. 3c). In other words, the 480 explanatory impact of dynamic variables increased over time in the ICU. Most of the 481 explanatory information in static variables contributed towards prediction of treatment 482 escalations earlier in patients' ICU stays (Fig. 3b). 483

484

485 Variables associated with next-day changes in TIL

486

During the days of consecutive TIL assessment that were eligible for Δ TimeSHAP 487 calculation (days 2-7), 575 patients (68% of population) experienced a total of 1,004 day-488 to-day changes in TIL^(Basic). The associative contributions of highest-impact variables 489 towards prediction of these changes - both for models trained on all variables and for 490 491 those trained without treatment variables – are visualised in Fig. 4. The number of points for each variable in Fig. 4 equals the number of times each variable was represented 492 across the 1,004 changes in TIL^(Basic). Moreover, we annotated several specific values of 493 categorical variables in Fig. 4 because of their visually consistent association with next-494 day TIL^(Basic) de-escalation (i.e., negative Δ TimeSHAP) or TIL^(Basic) escalation (i.e., 495 positive ΔTimeSHAP). Across the leading predictors of next-day changes in TIL^(Basic) (Fig. 496 497 4), we found the following categories of variables:

- the preceding trajectory of ICU management (e.g., extubation, prior trajectory of TIL, ending nasogastric feeding),
- age at admission,
- bleeding risk factors (e.g., history of taking anticoagulants, baseline platelet count),
- brain imaging results (e.g., traumatic subarachnoid haemorrhage, subdural haematoma, intraparenchymal haemorrhage),
- haemodynamics and intracranial hypertension (e.g., ICP, blood pressure, respiratory efficiency),
- markers of systemic inflammation (e.g., ventilator-associated pneumonia [which may also reflect long ventilation time], eosinophils),
- metabolic derangements (e.g., sodium, calcium, alanine aminotransferase),

- neurological function (e.g., Glasgow Coma Scale [GCS] eye and motor scores),
- protein biomarkers (e.g., neurofilament-light chain, total tau protein).
- 511
- Models with full variable set



512 513 Fig 4. Population-level variable contributions to prediction of changes in next-day TIL^(Basic) at days directly preceding a change in TIL^(Basic). The Δ TimeSHAP values on the left panel are from the models 514 trained on the full variable set whilst the Δ TimeSHAP values on the right panel are from the models trained 515 516 without clinician impressions or treatments. Δ TimeSHAP values are interpreted as the relative contributions of variables towards the difference in model prediction of next-day TIL(Basic) over the two days directly 517 preceding the change in TIL^(Basic) (Supplementary Methods S5). Therefore, the study population 518 represented in this figure is limited to patients who experienced a change in TIL^(Basic) after day two of ICU 519 520 stay (n = 575). A positive Δ TimeSHAP value signifies association with an increased likelihood of escalation in next-day TIL^(Basic), whereas a negative Δ TimeSHAP value signifies association with an increased 521 likelihood of de-escalation. The variables were selected by first identifying the ten variables with non-522 523 missing value tokens with the most negative median Δ TimeSHAP values across the population (above the 524 ellipses) and then, amongst the remaining variables, selecting the ten with non-missing value tokens with 525 the most positive median ΔTimeSHAP values (below the ellipses). Each point represents the mean 526 ΔTimeSHAP value, taken across all 20 repeated cross-validation partitions, for a token preceding an individual patient's change in TIL^(Basic). The number of points for each variable, therefore, indicates the 527 relative occurrence of that variable before changes in TIL^(Basic) in the study population. The colour of the 528 529 point represents the relative ordered value of a token within a variable, and for unordered variables (e.g., 530 patient status during GCS assessment), tokens were sorted alphanumerically (the sort index per possible 531 unordered variable token is provided in the CENTER-TBI data dictionary: https://www.center-532 tbi.eu/data/dictionary). Abbreviations: CVDs=cardiovascular diseases, ER=emergency room, F₁O₂=fraction 533 of inspired oxygen, GCS=Glasgow Coma Scale, ICP=intracranial pressure, PaO2=partial pressure of

oxygen, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1,
 VAP=ventilator-associated pneumonia.

536

The most robust predictors of next-day de-escalation in TIL^(Basic) were other clinical 537 538 indicators of treatment de-escalation (e.g., ending nasogastric feeding), improvement in patients' eye-opening responses, previous administration of barbiturates or propofol, and 539 sufficient control of ICP. Overall, the effects of predictors for TIL^(Basic) escalation were not 540 as robust as those for de-escalation (Fig. 4); however, stratifying the Δ TimeSHAP values 541 by the pre-transition TIL^(Basic) score revealed more consistent associations per level of 542 treatment intensity (Supplementary Fig. S5). For example, high ICP values were robustly 543 predictive of escalations from TIL^(Basic)=2, and the prior administration of certain therapies 544 could be predictive of a future escalation or de-escalation based on the current TIL^(Basic) 545 score (Supplementary Fig. S5). Apart from treatment variables, the factors that 546 contributed the most towards prediction of de-escalation from extreme ICP management 547 (i.e., TIL^(Basic)=4) were neurological improvements in motor and eye response with 548 sufficiently controlled ICP and high blood oxygen saturation (Supplementary Fig. S5). The 549 Δ TimeSHAP values of missing variables (Supplementary Fig. S6) demonstrated that 550 551 missingness of a variable (e.g., missing report of daily complications) could have a significant de-escalating associative effect on model output. 552

553

554 Conceptual model of changes in treatment intensity

555

556 We combined the results from the differential explanation of next-day changes in TIL^(Basic) 557 (Fig. 3b–c) and the variable contributions towards prediction of these events (Fig. 4) to 558 produce a conceptual model of day-to-day changes in treatment intensity (Fig. 5). Given 559 the considerable difference in explanation performance between day one and subsequent 560 days of ICU stay, we separated these explanation percentages in our model. 561



562 563

Fig 5. Conceptual diagram of factors explaining day-to-day changes in therapeutic intensity. The 564 percentage values represent the differential explanation of ordinal variation in next-day changes in TIL^(Basic) as measured by Somers' D_{xy}. The bolded percentage values represent the 95% confidence interval of 565 566 Somers' D_{xy} from days 2–6 of ICU stay, whilst the percentage values below them represent the 95% 567 confidence interval of Somers' Dxy from day 1 of ICU stay (Fig. 3c). The 95% confidence intervals were derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across 20 repeated 568 569 five-fold cross-validation partitions. The leading static and dynamic pathophysiological factors were 570 determined by gualitative categorisation of the variables with the highest contribution to next-day changes 571 in TIL^(Basic) based on Δ TimeSHAP values (Fig. 4). Abbreviations: TIL=Therapy Intensity Level, 572 TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1.

573

Discussion 574

575

We present the first approach to dynamic prediction of future therapy intensity levels (TIL) 576 in ICP-monitored TBI patients. The TILTomorrow modelling strategy allowed us to exploit 577 the full clinical context (2,008 variables) captured in a large neurotrauma dataset over 578 time to uncover factors associated with next-day changes in TIL^{(Basic), 19} By including 579 missing value tokens, models discovered meaningful patterns of missingness 580 (Supplementary Fig. S6).²⁰ Moreover, our approach mapped clinical events to evolving 581 predictions at each ordinal level of next-day TIL^(Basic), which is an improvement in 582 statistical power and clinical information over using a dichotomised measure of 583 therapeutic intensity (e.g., high-TIL therapies).¹⁵ 584

585

The main results of this study are summarised in the conceptual diagram of changes in 586 TIL^(Basic) (Fig. 5). Amongst all day-to-day steps, the transition from day one to day two had 587

the greatest number of changes in TIL^(Basic) (Fig. 2b), which were also the most predictable 588 (68% [95% CI: 65-72%] explanation, Fig. 3c). From day two onwards, the ordinal 589 explanation of changes in next-day TIL^(Basic) dropped to between 39% (95% CI: 32–47%) 590 591 and 51% (95% CI: 45–56%). This difference suggests that first-to-second-day changes in treatment intensity might have been the most systematic, possibly associated with 592 primary injury severity and initial patient responses to treatment (Fig. 3c). Later in ICU 593 stay, the predictive influence of a patient's treatment trajectory increased (mostly through 594 595 informative patterns of de-escalation, Fig. 3b), and that of static factors decreased (Fig. 3c). Whilst static factors are poor predictors of TIL^(Basic) on any given day (Fig. 3a and as 596 597 shown previously¹²), they achieve considerable discrimination performance in prediction of escalations up to day four (AUC: 0.70 [95% CI: 0.65-0.74], Fig. 3b). This may indicate 598 the potential of certain primary injury factors for justifying earlier intervention as to avoid 599 tolerating suboptimal ICP management for a few days. Apart from age, the highest-600 contributing static factors were space-occupying lesions (also reflected in a recent 601 study²⁸) and bleeding risk factors (Fig. 4), both of which can complicate ICP control. As 602 targets of TIL therapies, ICP and haemodynamic factors are expectedly high-contributing, 603 with different effects based on the pre-transition TIL^(Basic) score (Supplementary Fig. S5). 604 Metabolic complications (i.e., abnormalities in renal or liver function and electrolytic 605 606 imbalances) have previously been shown to be significantly more common in patients receiving high-TIL therapies¹² and an important marker for physiological endotyping.²⁹ 607 Moreover, in a prior study, serial protein biomarkers (in addition to GCS) were key 608 descriptors for clustering TBI patient trajectories in the ICU.³⁰ Therefore, the results from 609 these dynamic variables support the links between TIL and pathophysiology – including 610 systemic factors (e.g., metabolism and inflammation) – after TBI.⁷ This is potentially of 611 clinical importance since protein biomarkers are not measured serially as part of typical 612 613 routine care outside of research studies (e.g., CENTER-TBI) and a few centres. It is still uncertain whether serial biomarker measurement would improve care outcomes. 614 However, analysing the temporal dynamics of these biomarkers may not only enable a 615 more precise characterisation of patients' treatment needs but also elucidate biological 616 mechanisms underpinning variable treatment response. Finally, whilst we found no 617 significant difference in full-model prediction performance between next-day escalations 618 and de-escalations of TIL^(Basic) (Fig. 3b), high-impact predictors had a more robust signal 619 with de-escalations than they did with escalations (i.e., more consistently negative 620 Δ TimeSHAP values in Fig. 4). This suggests that escalation prediction may be the effect 621 of a complex interaction of factors which is difficult to perceive with Δ TimeSHAP values. 622 623

The underlying assumption of this work is that a more protocolised management of ICP 624 would also be more predictable based on the dynamic condition of a TBI patient. Even 625 with wide inter-centre variation in ICP-targeting treatment,¹⁴ we would expect the 626 measurable factors which rationally drive day-to-day changes in TIL to predict such 627 changes on an individual level. After day two, approximately half of the ordinal variation 628 in day-to-day changes in TIL^(Basic) is unexplained by the full CENTER-TBI variable set. 629 and we propose four reasons for this remaining uncertainty (Fig. 5). First, certain clinical 630 631 events or complications that could suddenly trigger a (de-)escalation in TIL (e.g., 632 sustained rise in ICP) might not have been predictable from the day before. Second, there are probably important physiological factors, either unmeasured or not included in our 633

variable set, which would have improved TIL prediction. Most notably, high-resolution 634 waveforms of ICP³¹ and arterial blood pressure (ABP) and their derived metrics (e.g., 635 pressure-time dose³² and vascular reactivity³³) are more likely to elucidate ICP 636 637 management decisions than the bihourly clinician-recorded ICP or CPP values available in our variable set.³⁴ Prior analyses of additional physiological modalities – e.g., cerebral 638 microdialysis,³⁵ automated pupillometry,^{36,37} and motion sensing³⁸ – have also 639 demonstrated independent associations with TIL or other short-term endpoints after TBI. 640 Third, assuming different centres have different protocols for ICP management, there may 641 not have been enough patient representation across the spectrum of TBI severity from 642 each centre for TILTomorrow to learn centre-specific guidelines. Fourth, a part of ICP 643 644 management may be driven by the personal preferences of clinicians in deviation from general guidelines. At the same time, we recognise that predictability does not guarantee 645 a systematised delivery of care. We therefore investigated differential explanation of (Fig. 646 3b-c) and specific variable contributions towards (Fig. 4) changes in TIL to bridge 647 prediction performance to a plausible concept of ICP management (Fig. 5). 648

649

Our results support the use of TIL as an intermediate outcome after TBI.⁷ Specific 650 categories of pathophysiological variables - both static and dynamic - associate well with 651 changes in TIL (Fig. 4 and 5). Since TIL rates the relative risk and complexity of 652 653 administered treatments, it is logical to minimise TIL when all other factors are held equal. On the other hand, TIL is also a complicated marker of pathophysiology. Since around 654 half of the ordinal variation in changes in TIL is not explained by measured variables (Fig. 655 5), we hypothesise that TIL's sensitivity to pathophysiology is partially confounded by the 656 personal preferences of clinical teams. Nevertheless, TIL was previously shown to be a 657 stronger indicator of refractory intracranial hypertension than ICP itself and, thus, a more 658 suitable intermediate endpoint for TBI management.⁷ Since the full information pertaining 659 to TIL was only date-stamped in CENTER-TBI, the highest resolution at which we could 660 assess TIL^(Basic) was once per calendar day (Table 1). However, clinicians were also 661 asked to record qualitatively whether treatment intensity was decreasing or increasing 662 every four hours, and these indications (from the day before a change in TIL^(Basic)) were 663 amongst the strongest predictors of next-day changes in TIL^(Basic) (Fig. 4). This result 664 supports a higher resolution TIL for monitoring pathophysiological severity; however, daily 665 TIL scores have been shown to be reliable estimates of hourly TIL scores,⁹ and CENTER-666 TBI has demonstrated the practical feasibility of daily TIL assessment for a large-scale 667 study (≤2.4% missingness, Fig. 2a). 668

669

TILTomorrow can potentially be useful in other heterogeneous-data-intensive clinical 670 domains as a framework for decoding factors tied to treatment decision-making or other 671 672 dynamic endpoints. This can inform the design of future causal inference models of individualised treatment effects from observational data.³⁹ TILTomorrow was not 673 conceived for clinical deployment and should not be used for real-time decision support 674 675 due to concerns of self-fulfilling prophecies, generalisability, and variable robustness.⁴⁰ Our focus was on explanatory modelling, to derive insightful patterns from the CENTER-676 TBI data and quantify the predictability of ICP management. Furthermore, ΔTimeSHAP 677 678 values on observational data are merely associative and cannot be interpreted for causal inference. We used TimeSHAP in this work to highlight potential areas of investigation 679

from a wider, data-driven approach. Pathophysiological predictors of the need for higher TIL (Fig. 4 and 5) could be useful for improving the timing and precision of future clinical decision-making (e.g., performing decompressive craniectomy in a timely but targeted way) but would require more evidence and feasibility studies than just their predictive power in our data.

685

We recognise several additional limitations in this study. TILTomorrow discretised both 686 numerical variables into binned tokens and time into daily windows, which caused some 687 loss of information. Limited by the resolution of available TIL assessments, we chose a 688 daily time window to avoid inconsistent lead times in our prediction task (Fig. 1a). The 689 690 highest resolution of regularly recorded variables (e.g., ICP) in the CENTER-TBI core study is once every two hours,¹³ and, since TILTomorrow takes the unique set of tokens 691 per daily window prior to embedding, these numerical variables would be reduced to the 692 unique set of quantiles represented in a day (Fig. 1b). An encoding strategy which can 693 integrate high-resolution ICP, CPP, and other clinical information into broader time 694 windows may improve prediction performance. Additionally, the daily TIL^(Basic) score 695 accounts for 33% of the information in the full, 38-point TIL score.⁷ As explained in the 696 Methods, we used TIL^(Basic) as the model endpoint over the full TIL score since it would 697 enable us to uncover factors associated with changes across specific, interpretable bands 698 699 of treatment intensity (Table 1). Nevertheless, a regression-based prediction of next-day full TIL may capture more nuanced patterns of factors associated with changes in ICP 700 management. Finally, our results may encode recruitment, collection, and clinical biases 701 native to our European patient set. Selective recording of clinical data – with selective 702 missingness - may have biased our analyses, and findings may not generalise to other 703 populations.⁴¹ Given the broad inter-centre variation in ICP-targeted care,¹⁴ the results of 704 705 TILTomorrow are likely to vary considerably depending on the protocols of specific centres. We encourage investigators to apply the TILTomorrow approach to other 706 longitudinal, granular ICU datasets of TBI patients - particularly in low- and middle-707 income countries where the burden of TBI is disproportionately higher⁴² – and compare 708 709 their results.

710

711 Data and code availability

712

Individual participant data, including data dictionary, the study protocol, and analysis scripts are available online, conditional to approved study proposal, with no end date. Interested investigators must submit a study proposal to the management committee at <u>https://www.center-tbi.eu/data</u>. Signed confirmation of a data access agreement is required, and all access must comply with regulatory restrictions imposed on the original study.

719

All code used in this project can be found at the following online repository:
 <u>https://github.com/sbhattacharyay/TILTomorrow</u> (DOI: 10.5281/zenodo.11060742).

- 723 Acknowledgments
- 724

This research was supported by the National Institute for Health Research (NIHR) Brain 725 Injury MedTech Co-operative. CENTER-TBI was supported by the European Union 7th 726 Framework programme (EC grant 602150). Additional funding was obtained from the 727 728 Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA), and from NeuroTrauma Sciences (USA). CENTER-TBI also 729 acknowledges interactions and support from the International Initiative for TBI Research 730 (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded 731 by the Medical Research Council (MR N013433-1) and by a Gates Cambridge 732 Scholarship. The funders had no role in study design, data collection and analysis, 733 decision to publish, or preparation of the manuscript. 734

735

We are grateful to the patients and families of our study for making our efforts to improve
TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University)
for offering comments on the manuscript.

739

740 The CENTER-TBI investigators and participants

741

The co-lead investigators of CENTER-TBI are designated with an asterisk (*), and their contact email addresses are listed below.

744

Cecilia Åkerlund¹, Krisztina Amrein², Nada Andelic³, Lasse Andreassen⁴, Audny Anke⁵, 745 Anna Antoni⁶, Gérard Audibert⁷, Philippe Azouvi⁸, Maria Luisa Azzolini⁹, Ronald Bartels¹⁰, 746 Pál Barzó¹¹, Romuald Beauvais¹², Ronny Beer¹³, Bo-Michael Bellander¹⁴, Antonio Belli¹⁵, 747 Habib Benali¹⁶, Maurizio Berardino¹⁷, Luigi Beretta⁹, Morten Blaabjerg¹⁸, Peter Bragge¹⁹, 748 Alexandra Brazinova²⁰, Vibeke Brinck²¹, Joanne Brooker²², Camilla Brorsson²³, Andras 749 Buki²⁴, Monika Bullinger²⁵, Manuel Cabeleira²⁶, Alessio Caccioppola²⁷, Emiliana 750 Calappi²⁷, Maria Rosa Calvi⁹, Peter Cameron²⁸, Guillermo Carbayo Lozano²⁹, Marco 751 Carbonara²⁷, Simona Cavallo¹⁷, Giorgio Chevallard³⁰, Arturo Chieregato³⁰, Giuseppe 752 Citerio^{31,32}, Hans Clusmann³³, Mark Coburn³⁴, Jonathan Coles³⁵, Jamie D. Cooper³⁶, 753 Marta Correia³⁷, Amra Čović³⁸, Nicola Curry³⁹, Endre Czeiter²⁴, Marek Czosnyka²⁶, Claire 754 Dahyot-Fizelier⁴⁰, Paul Dark⁴¹, Helen Dawes⁴², Véronique De Keyser⁴³, Vincent Degos¹⁶, 755 Francesco Della Corte⁴⁴, Hugo den Boogert¹⁰, Bart Depreitere⁴⁵, Đula Đilvesi⁴⁶, Abhishek Dixit⁴⁷, Emma Donoghue²², Jens Dreier⁴⁸, Guy-Loup Dulière⁴⁹, Ari Ercole⁴⁷, Patrick 756 757 Esser⁴², Erzsébet Ezer⁵⁰, Martin Fabricius⁵¹, Valery L. Feigin⁵², Kelly Foks⁵³, Shirin 758 Frisvold⁵⁴, Alex Furmanov⁵⁵, Pablo Gagliardo⁵⁶, Damien Galanaud¹⁶, Dashiell Gantner²⁸. 759 Guoyi Gao⁵⁷, Pradeep George⁵⁸, Alexandre Ghuysen⁵⁹, Lelde Giga⁶⁰, Ben Glocker⁶¹, 760 Jagoš Golubovic⁴⁶, Pedro A. Gomez⁶², Johannes Gratz⁶³, Benjamin Gravesteijn⁶⁴, 761 Francesca Grossi⁴⁴, Russell L. Gruen⁶⁵, Deepak Gupta⁶⁶, Juanita A. Haagsma⁶⁴, Iain 762 Haitsma⁶⁷, Raimund Helbok¹³, Eirik Helseth⁶⁸, Lindsay Horton⁶⁹, Jilske Huijben⁶⁴, Peter 763 J. Hutchinson⁷⁰, Bram Jacobs⁷¹, Stefan Jankowski⁷², Mike Jarrett²¹, Ji-yao Jiang⁵⁸, Faye 764 Johnson⁷³, Kelly Jones⁵², Mladen Karan⁴⁶, Angelos G. Kolias⁷⁰, Erwin Kompanje⁷⁴, Daniel Kondziella⁵¹, Evgenios Kornaropoulos⁴⁷, Lars-Owe Koskinen⁷⁵, Noémi Kovács⁷⁶, Ana 765 766 Kowark⁷⁷, Alfonso Lagares⁶², Linda Lanyon⁵⁸, Steven Laureys⁷⁸, Fiona Lecky^{79,80}, Didier 767 Ledoux⁷⁸, Rolf Lefering⁸¹, Valerie Legrand⁸², Aurelie Lejeune⁸³, Leon Levi⁸⁴, Roger 768 Lightfoot⁸⁵, Hester Lingsma⁶⁴, Andrew I.R. Maas^{43,86,*}, Ana M. Castaño-León⁶², Marc 769 Maegele⁸⁷, Marek Majdan²⁰, Alex Manara⁸⁸, Geoffrey Manley⁸⁹, Costanza Martino⁹⁰, 770

Hugues Maréchal⁴⁹, Julia Mattern⁹¹, Catherine McMahon⁹², Béla Melegh⁹³, David Menon^{47,*}, Tomas Menovsky^{43,86}, Ana Mikolic⁶⁴, Benoit Misset⁷⁸, Visakh 771 772 Muraleedharan⁵⁸, Lynnette Murray²⁸, Ancuta Negru⁹⁴, David Nelson¹, Virginia 773 Newcombe⁴⁷, Daan Nieboer⁶⁴, József Nyirádi², Otesile Olubukola⁷⁹, Matej Oresic⁹⁵, 774 Fabrizio Ortolano²⁷, Aarno Palotie^{96,97,98}, Paul M. Parizel⁹⁹, Jean-François Payen¹⁰⁰, 775 Natascha Perera¹², Vincent Perlbarg¹⁶, Paolo Persona¹⁰¹, Wilco Peul¹⁰², Anna Piippo-776 Karjalainen¹⁰³, Matti Pirinen⁹⁶, Dana Pisica⁶⁴, Horia Ples⁹⁴, Suzanne Polinder⁶⁴, Inigo 777 Pomposo²⁹, Jussi P. Posti¹⁰⁴, Louis Puybasset¹⁰⁵, Andreea Radoi¹⁰⁶, Arminas 778 Ragauskas¹⁰⁷, Rahul Raj¹⁰³, Malinka Rambadagalla¹⁰⁸, Isabel Retel Helmrich⁶⁴, Jonathan 779 Rhodes¹⁰⁹, Sylvia Richardson¹¹⁰, Sophie Richter⁴⁷, Samuli Ripatti⁹⁶, Saulius Rocka¹⁰⁷, 780 Cecilie Roe¹¹¹, Olav Roise^{112,113}, Jonathan Rosand¹¹⁴, Jeffrey V. Rosenfeld¹¹⁵, Christina 781 Rosenlund¹¹⁶, Guy Rosenthal⁵⁵, Rolf Rossaint⁷⁷, Sandra Rossi¹⁰¹, Daniel Rueckert⁶¹ 782 Martin Rusnák¹¹⁷, Juan Sahuquillo¹⁰⁶, Oliver Sakowitz^{91,118}, Renan Sanchez-Porras¹¹⁸, 783 Janos Sandor¹¹⁹, Nadine Schäfer⁸¹, Silke Schmidt¹²⁰, Herbert Schoechl¹²¹, Guus 784 Schoonman¹²², Rico Frederik Schou¹²³, Elisabeth Schwendenwein⁶, Charlie Sewalt⁶⁴, 785 Ranjit D. Singh¹⁰², Toril Skandsen^{124,125}, Peter Smielewski²⁶, Abayomi Sorinola¹²⁶, 786 Emmanuel Stamatakis⁴⁷, Simon Stanworth³⁹, Robert Stevens¹²⁷, William Stewart¹²⁸, 787 Ewout W. Steyerberg^{64,129}, Nino Stocchetti¹³⁰, Nina Sundström¹³¹, Riikka Takala¹³², 788 Viktória Tamás¹²⁶, Tomas Tamosuitis¹³³, Mark Steven Taylor²⁰, Aurore Thibaut⁷⁸, Braden 789 Te Ao⁵², Olli Tenovuo¹⁰⁴, Alice Theadom⁵², Matt Thomas⁸⁸, Dick Tibboel¹³⁴, Marjolein 790 Timmers⁷⁴, Christos Tolias¹³⁵, Tony Trapani²⁸, Cristina Maria Tudora⁹⁴, Andreas 791 Unterberg⁹¹, Peter Vajkoczy¹³⁶, Shirley Vallance²⁸, Egils Valeinis⁶⁰, Zoltán Vámos⁵⁰, 792 Mathieu van der Jagt¹³⁷, Gregory Van der Steen⁴³, Joukje van der Naalt⁷¹, Jeroen T.J.M. 793 van Dijck¹⁰², Inge A. M. van Erp¹⁰², Thomas A. van Essen¹⁰², Wim Van Hecke¹³⁸, Caroline 794 van Heugten¹³⁹, Ernest van Veen⁶⁴, Thijs Vande Vyvere¹⁴⁰, Roel P. J. van Wijk¹⁰², Alessia 795 Vargiolu³², Emmanuel Vega⁸³, Kimberley Velt⁶⁴, Jan Verheyden¹³⁸, Paul M. Vespa¹⁴¹, 796 Anne Vik^{124,142}, Rimantas Vilcinis¹³³, Victor Volovici⁶⁷, Nicole von Steinbüchel³⁸, Daphne 797 Voormolen⁶⁴, Petar Vulekovic⁴⁶, Kevin K.W. Wang¹⁴³, Daniel Whitehouse⁴⁷, Eveline 798 Wiegers⁶⁴, Guy Williams⁴⁷, Lindsay Wilson⁶⁹, Stefan Winzeck⁴⁷, Stefan Wolf¹⁴⁴, Zhihui 799 Yang¹¹⁴, Peter Ylén¹⁴⁵, Alexander Younsi⁹¹, Frederick A. Zeiler^{47,146}, Veronika 800 Zelinkova²⁰. Agate Ziverte⁶⁰. Tommaso Zoerle²⁷ 801

- 802
- ¹Department of Physiology and Pharmacology, Section of Perioperative Medicine and
 Intensive Care, Karolinska Institutet, Stockholm, Sweden
- ²János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- ³Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation,
 Oslo University Hospital and University of Oslo, Oslo, Norway
- ⁴Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway
- ⁵Department of Physical Medicine and Rehabilitation, University Hospital Northern
 Norway, Tromso, Norway
- ⁶Trauma Surgery, Medical University Vienna, Vienna, Austria
- ⁷Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy,
 France
- ⁸Raymond Poincare hospital, Assistance Publique Hopitaux de Paris, Paris, France
- ⁹Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan,
- 816 Italy

- ¹⁰Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The
 Netherlands
- ¹¹Department of Neurosurgery, University of Szeged, Szeged, Hungary
- ¹²International Projects Management, ARTTIC, Munchen, Germany
- ¹³Department of Neurology, Neurological Intensive Care Unit, Medical University of
 Innsbruck, Innsbruck, Austria
- ¹⁴Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska
 ¹⁴Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska
 ¹⁴Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska
- ¹⁵NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- ¹⁶Anesthesie-Réanimation, Assistance Publique Hopitaux de Paris, Paris, France
- ¹⁷Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino Orthopedic and Trauma Center, Torino, Italy
- ¹⁸Department of Neurology, Odense University Hospital, Odense, Denmark
- ¹⁹BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria,
 Australia
- ²⁰Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
 ⁸³³ University, Trnava, Slovakia
- ²¹Quesgen Systems Inc., Burlingame, California, USA
- ²²Australian & New Zealand Intensive Care Research Centre, Department of
 Epidemiology and Preventive Medicine, School of Public Health and Preventive
 Medicine, Monash University, Melbourne, Australia
- ²³Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- ²⁴Department of Neurosurgery, Medical School, University of Pécs, Hungary and
 Neurotrauma Research Group, János Szentágothai Research Centre, University of
 Pécs, Hungary
- ²⁵Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf,
 Hamburg, Germany
- ²⁶Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University
 of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- ²⁷Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- ²⁸ANZIC Research Centre, Monash University, Department of Epidemiology and
 Preventive Medicine, Melbourne, Victoria, Australia
- ²⁹Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
- ³⁰NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- ³¹School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
- ³²NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo
 dei Tintori, Monza, Italy
- ³³Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen,
 Germany
- ³⁴Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn,
 Bonn, Germany
- ³⁵Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS
 Foundation Trust, Cambridge, UK
- ³⁶School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne,
 Victoria, Australia
- ³⁷Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

863 ³⁸Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany 864 ³⁹Oxford University Hospitals NHS Trust, Oxford, UK 865 866 ⁴⁰Intensive Care Unit, CHU Poitiers, Potiers, France ⁴¹University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, 867 Salford Royal Hospital NHS Foundation Trust, Salford, UK 868 ⁴²Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes 869 870 University, Oxford, UK ⁴³Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium 871 872 ⁴⁴Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, 873 Italy ⁴⁵Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium 874 ⁴⁶Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, 875 University of Novi Sad, Novi Sad, Serbia 876 ⁴⁷Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, 877 UK 878 ⁴⁸Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate 879 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute 880 of Health, Berlin, Germany 881 ⁴⁹Intensive Care Unit, CHR Citadelle, Liège, Belgium 882 ⁵⁰Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, 883 884 Hungary 885 ⁵¹Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark 886 ⁵²National Institute for Stroke and Applied Neurosciences, Faculty of Health and 887 888 Environmental Studies, Auckland University of Technology, Auckland, New Zealand ⁵³Department of Neurology, Erasmus MC, Rotterdam, the Netherlands 889 ⁵⁴Department of Anesthesiology and Intensive care, University Hospital Northern Norway, 890 Tromso, Norway 891 ⁵⁵Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, 892 Israel 893 894 ⁵⁶Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain 895 ⁵⁷Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotona University/school of medicine, Shanghai, China 896 897 ⁵⁸Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm. Sweden 898 ⁵⁹Emergency Department, CHU, Liège, Belgium 899 ⁶⁰Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia 900 ⁶¹Department of Computing, Imperial College London, London, UK 901 ⁶²Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain 902 ⁶³Department of Anesthesia, Critical Care and Pain Medicine, Medical University of 903 904 Vienna, Austria ⁶⁴Department of Public Health, Erasmus Medical Center-University Medical Center, 905 Rotterdam. The Netherlands 906 907 ⁶⁵College of Health and Medicine, Australian National University, Canberra, Australia

- ⁶⁶Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All
 India Institute of Medical Sciences, New Delhi-110029, India
- ⁶⁷Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- ⁶⁸Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- ⁶⁹Division of Psychology, University of Stirling, Stirling, UK
- ⁷⁰Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
 Hospital & University of Cambridge, Cambridge, UK
- ⁷¹Department of Neurology, University of Groningen, University Medical Center
 Groningen, Groningen, Netherlands
- ⁷²Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,
 UK
- ⁷³Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford,
 UK
- ⁷⁴Department of Intensive Care and Department of Ethics and Philosophy of Medicine,
 Erasmus Medical Center, Rotterdam, The Netherlands
- ⁷⁵Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- ⁷⁶Hungarian Brain Research Program Grant No. KTIA_13_NAP-A-II/8, University of
 Pécs, Pécs, Hungary
- ⁷⁷Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- ⁷⁸Cyclotron Research Center, University of Liège, Liège, Belgium
- ⁷⁹Centre for Urgent and Emergency Care Research (CURE), Health Services Research
 Section, School of Health and Related Research (ScHARR), University of Sheffield,
 Sheffield, UK
- 931 ⁸⁰Emergency Department, Salford Royal Hospital, Salford UK
- ⁸¹Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,
 Cologne, Germany
- ⁸²VP Global Project Management CNS, ICON, Paris, France
- ⁸³Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- ⁹³⁶ ⁸⁴Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- ⁸⁵Department of Anesthesiology & Intensive Care, University Hospitals Southhampton
 NHS Trust, Southhampton, UK
- ⁸⁶Department of Translational Neuroscience, Faculty of Medicine and Health Science,
 ⁹⁴⁰University of Antwerp, Antwerp, Belgium
- ⁸⁷Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic
 Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- ⁸⁸Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- ⁸⁹Department of Neurological Surgery, University of California, San Francisco, California,
 USA
- ⁹⁰Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- ⁹¹Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- ⁹²Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK
- ⁹³Department of Medical Genetics, University of Pécs, Pécs, Hungary
- ⁹⁴Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
 Romania
- ⁹⁵School of Medical Sciences, Örebro University, Örebro, Sweden
- ⁹⁶Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

- ⁹⁷Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric &
 Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of
 Neurology, Massachusetts General Hospital, Boston, MA, USA
- ⁹⁸Program in Medical and Population Genetics; The Stanley Center for Psychiatric
 Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- ⁹⁹Department of Radiology, University of Antwerp, Edegem, Belgium
- ¹⁰⁰Department of Anesthesiology & Intensive Care, University Hospital of Grenoble,
 Grenoble, France
- ¹⁰¹Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di
 Padova, Padova, Italy
- ¹⁰²Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and
 Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
- ¹⁰³Department of Neurosurgery, Helsinki University Central Hospital
- ¹⁰⁴Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury
 Centre, Turku University Hospital and University of Turku, Turku, Finland
- ¹⁰⁵Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,
 Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris,
 France
- ¹⁰⁶Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron
 Research Institute, Barcelona, Spain
- ¹⁰⁷Department of Neurosurgery, Kaunas University of technology and Vilnius University,
 Vilnius, Lithuania
- ¹⁰⁸Department of Neurosurgery, Rezekne Hospital, Latvia
- ¹⁰⁹Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University
 of Edinburg, Edinburgh, UK
- ¹¹⁰Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- ⁹⁸⁰ ¹¹¹Department of Physical Medicine and Rehabilitation, Oslo University
 ⁹⁸¹ Hospital/University of Oslo, Oslo, Norway
- ¹¹²Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- ¹¹³Institue of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- ¹¹⁴Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts
 General Hospital, Boston MA, USA
- ¹¹⁵National Trauma Research Institute, The Alfred Hospital, Monash University,
 Melbourne, Victoria, Australia
- ¹¹⁶Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- ⁹⁸⁹ ¹¹⁷International Neurotrauma Research Organisation, Vienna, Austria
- ¹¹⁸Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- ¹¹⁹Division of Biostatistics and Epidemiology, Department of Preventive Medicine,
 ⁹⁹²University of Debrecen, Debrecen, Hungary
- ¹²⁰Department Health and Prevention, University Greifswald, Greifswald, Germany
- ¹²¹Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg,
 Austria
- ¹²²Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- ¹²³Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital,
 Odense, Denmark

- ¹²⁴Department of Neuromedicine and Movement Science, Norwegian University of
 Science and Technology, NTNU, Trondheim, Norway
- ¹²⁵Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim
 University Hospital, Trondheim, Norway
- ¹²⁶Department of Neurosurgery, University of Pécs, Pécs, Hungary
- ¹²⁷Division of Neuroscience Critical Care, John Hopkins University School of Medicine,
 Baltimore, USA
- ¹²⁸Department of Neuropathology, Queen Elizabeth University Hospital and University of
 Glasgow, Glasgow, UK
- ¹²⁹Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center,
 Leiden, The Netherlands
- ¹³⁰Department of Pathophysiology and Transplantation, Milan University, and
 Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,
 Milano, Italy
- ¹³¹Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå,
 Sweden
- ¹³²Perioperative Services, Intensive Care Medicine and Pain Management, Turku
 University Hospital and University of Turku, Turku, Finland
- ¹³³Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- ¹³⁴Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia
 Children's Hospital, Rotterdam, The Netherlands
- ¹³⁵Department of Neurosurgery, Kings college London, London, UK
- ¹³⁶Neurologie, Neurochirurgie und Psychiatrie, Charité Universitätsmedizin Berlin,
 Berlin, Germany
- ¹³⁷Department of Intensive Care Adults, Erasmus MC– University Medical Center
 Rotterdam, Rotterdam, the Netherlands
- ¹³⁸icoMetrix NV, Leuven, Belgium
- ¹³⁹Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
 University, Oxford, UK
- ¹⁴⁰Radiology Department, Antwerp University Hospital, Edegem, Belgium
- ¹⁴¹Director of Neurocritical Care, University of California, Los Angeles, USA
- ¹⁴²Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital,
 Trondheim, Norway
- ¹⁴³Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
- ¹⁴⁴Department of Neurosurgery, Charité Universitätsmedizin Berlin, corporate member
 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
 Health, Berlin, Germany
- ¹⁰³⁶ ¹⁴⁵VTT Technical Research Centre, Tampere, Finland
- ¹⁴⁶Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences,
 University of Manitoba, Winnipeg, MB, Canada
- 1039
- 1040 *Co-lead investigators: <u>andrew.maas@uza.be</u> (AIRM) and <u>dkm13@cam.ac.uk</u> (DM)
- 1041

1042 **References**

- Meyfroidt G, Bouzat P, Casaer MP, *et al.* Management of moderate to severe traumatic brain injury: an update for the intensivist. *Intensive Care Med* 2022; 48: 649–66.
- 1047 2 Maas AIR, Menon DK, Adelson PD, *et al.* Traumatic brain injury: integrated
 1048 approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;
 1049 16: 987–1048.
- Maas AIR, Menon DK, Manley GT, *et al.* Traumatic brain injury: progress and
 challenges in prevention, clinical care, and research. *Lancet Neurol* 2022; **21**: 1004–
 60.
- Hawryluk GWJ, Aguilera S, Buki A, *et al.* A management algorithm for patients with
 intracranial pressure monitoring: the Seattle International Severe Traumatic Brain
 Injury Consensus Conference (SIBICC). *Intensive Care Med* 2019; **45**: 1783–94.
- 1056 5 Carney N, Totten AM, O'Reilly C, *et al.* Guidelines for the Management of Severe
 1057 Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017; **80**: 6.
- 1058 6 Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. *N Engl J Med* 2014;
 1059 370: 2121–30.
- 7 Bhattacharyay S, Beqiri E, Zuercher P, *et al.* Therapy Intensity Level Scale for
 Traumatic Brain Injury: Clinimetric Assessment on Neuro-Monitored Patients Across
 52 European Intensive Care Units. *J Neurotrauma* 2024; **41**: 887–909.
- 1063 8 Maas AIR, Harrison-Felix CL, Menon D, *et al.* Standardizing Data Collection in
 1064 Traumatic Brain Injury. *J Neurotrauma* 2011; 28: 177–87.
- 1065 9 Zuercher P, Groen JL, Aries MJH, *et al.* Reliability and Validity of the Therapy
 1066 Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to
 1067 Assess Management of Intracranial Pressure in Traumatic Brain Injury. *J*1068 *Neurotrauma* 2016; **33**: 1768–74.
- 10 Maas AIR, Menon DK, Steyerberg EW, *et al.* Collaborative European NeuroTrauma
 Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective
 Longitudinal Observational Study. *Neurosurgery* 2015; **76**: 67–80.
- 11 Steyerberg EW, Wiegers E, Sewalt C, *et al.* Case-mix, care pathways, and
 outcomes in patients with traumatic brain injury in CENTER-TBI: a European
 prospective, multicentre, longitudinal, cohort study. *Lancet Neurol* 2019; **18**: 923–34.
- 1075 12 Huijben JA, Dixit A, Stocchetti N, *et al.* Use and impact of high intensity treatments
 in patients with traumatic brain injury across Europe: a CENTER-TBI analysis. *Crit* 1077 *Care* 2021; **25**: 78.

- 13 Bhattacharyay S, Caruso PF, Åkerlund C, *et al.* Mining the contribution of intensive
 care clinical course to outcome after traumatic brain injury. *Npj Digit Med* 2023; 6: 1–
 11.
- 14 Huijben JA, Wiegers EJA, Lingsma HF, *et al.* Changing care pathways and
 between-center practice variations in intensive care for traumatic brain injury across
 Europe: a CENTER-TBI analysis. *Intensive Care Med* 2020; **46**: 995–1004.
- 15 Bhattacharyay S, Milosevic I, Wilson L, *et al.* The leap to ordinal: Detailed functional
 prognosis after traumatic brain injury with a flexible modelling approach. *PLOS ONE* 2022; **17**: e0270973.
- 1087 16 Doiron D, Marcon Y, Fortier I, Burton P, Ferretti V. Software Application Profile: Opal
 and Mica: open-source software solutions for epidemiological data management,
 harmonization and dissemination. *Int J Epidemiol* 2017; **46**: 1372–8.
- 17 Monteiro M, Newcombe VFJ, Mathieu F, *et al.* Multiclass semantic segmentation
 and quantification of traumatic brain injury lesions on head CT using deep learning:
 an algorithm development and multicentre validation study. *Lancet Digit Health* 2020;
 2: e314–22.
- 1094 18 Jain S, Vyvere TV, Terzopoulos V, *et al.* Automatic Quantification of Computed
 1095 Tomography Features in Acute Traumatic Brain Injury. *J Neurotrauma* 2019; 36:
 1096 1794–803.
- 1097 19 Deasy J, Liò P, Ercole A. Dynamic survival prediction in intensive care units from
 heterogeneous time series without the need for variable selection or curation. *Sci* 1099 *Rep* 2020; **10**: 22129.
- 20 Ercole A, Dixit A, Nelson DW, *et al.* Imputation strategies for missing baseline
 neurological assessment covariates after traumatic brain injury: A CENTER-TBI
 study. *PLOS ONE* 2021; **16**: e0253425.
- 1103 21 Tsamardinos I, Greasidou E, Borboudakis G. Bootstrapping the out-of-sample
 1104 predictions for efficient and accurate cross-validation. *Mach Learn* 2018; **107**: 1895–
 1105 922.
- 22 Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A
 calibration hierarchy for risk models was defined: from utopia to empirical data. *J Clin Epidemiol* 2016; **74**: 167–76.
- Somers RH. A New Asymmetric Measure of Association for Ordinal Variables. *Am Sociol Rev* 1962; **27**: 799–811.
- 24 Van Calster B, Van Belle V, Vergouwe Y, Steyerberg EW. Discrimination ability of
 prediction models for ordinal outcomes: Relationships between existing measures
 and a new measure. *Biom J* 2012; **54**: 674–85.

25 Bento J, Saleiro P, Cruz AF, Figueiredo MAT, Bizarro P. TimeSHAP: Explaining
 Recurrent Models through Sequence Perturbations. In: Proceedings of the 27th ACM
 SIGKDD Conference on Knowledge Discovery & Data Mining. New York, NY, USA:

- Association for Computing Machinery, 2021: 2565–73.
- 1118 26 Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. In:
- Guyon I, Luxburg UV, Bengio S, *et al.*, eds. Advances in Neural InformationProcessing Systems 30. NIPS, 2017: 4765–74.
- 1121 27 Shapley LS. A Value for n-Person Games. In: Contributions to the Theory of Games
 1122 II. Princeton University Press, 1953: 307–18.
- 1123 28 Brossard C, Grèze J, de Busschère J-A, *et al.* Prediction of therapeutic intensity
 1124 level from automatic multiclass segmentation of traumatic brain injury lesions on CT1125 scans. *Sci Rep* 2023; **13**: 20155.
- 29 Åkerlund CAI, Holst A, Stocchetti N, *et al.* Clustering identifies endotypes of
 traumatic brain injury in an intensive care cohort: a CENTER-TBI study. *Crit Care*2022; **26**: 228.
- 30 Åkerlund CAI, Holst A, Bhattacharyay S, *et al.* Clinical descriptors of disease
 trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study. *Lancet Neurol* 2024; **23**: 71–80.
- 1132 31 Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. J
 1133 Neurol Neurosurg Psychiatry 2004; **75**: 813–21.

1134 32 Åkerlund CAI, Donnelly J, Zeiler FA, *et al.* Impact of duration and magnitude of
 1135 raised intracranial pressure on outcome after severe traumatic brain injury: A
 1136 CENTER-TBI high-resolution group study. *PLOS ONE* 2020; **15**: e0243427.

- 33 Beqiri E, Ercole A, Aries MJH, *et al.* Towards autoregulation-oriented management
 after traumatic brain injury: increasing the reliability and stability of the CPPopt
 algorithm. *J Clin Monit Comput* 2023; **37**: 963–76.
- 34 Zoerle T, Birg T, Carbonara M, *et al.* Accuracy of Manual Intracranial Pressure
 Recording Compared to a Computerized High-Resolution System: A CENTER-TBI
 Analysis. *Neurocrit Care* 2023; **38**: 781–90.
- 1143 35 Eiden M, Christinat N, Chakrabarti A, *et al.* Discovery and validation of temporal
 1144 patterns involved in human brain ketometabolism in cerebral microdialysis fluids of
 1145 traumatic brain injury patients. *eBioMedicine* 2019; **44**: 607–17.
- 36 Banco P, Taccone FS, Sourd D, *et al.* Prediction of neurocritical care intensity
 through automated infrared pupillometry and transcranial doppler in blunt traumatic
 brain injury: the NOPE study. *Eur J Trauma Emerg Surg* 2024; published online Jan
 16. DOI:10.1007/s00068-023-02435-1.

- 1150 37 Luz Teixeira T, Peluso L, Banco P, *et al.* Early Pupillometry Assessment in
 1151 Traumatic Brain Injury Patients: A Retrospective Study. *Brain Sci* 2021; **11**: 1657.
- 38 Bhattacharyay S, Rattray J, Wang M, *et al.* Decoding accelerometry for classification
 and prediction of critically ill patients with severe brain injury. *Sci Rep* 2021; **11**:
 23654.
- 39 Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World Patient Data to
 Individualized Treatment Effects Using Machine Learning: Current and Future
 Methods to Address Underlying Challenges. *Clin Pharmacol Ther* 2020; **109**: 87–100.
- 40 Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An
 overview of clinical decision support systems: benefits, risks, and strategies for
 success. *Npj Digit Med* 2020; **3**: 1–10.
- 41 Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability
 in clinical research and machine learning in health care. *Lancet Digit Health* 2020; 2:
 e489–92.
- 42 Clark D, Joannides A, Adeleye AO, *et al.* Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study. *Lancet Neurol* 2022; **21**: 438–49.